MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Clovis Oncology, Inc.

Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286
From Clovis Oncology, Inc.
Via Business Wire
Tickers CLVS
Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agreement
From Clovis Oncology, Inc.
Via Business Wire
Tickers CLVS
Clovis Oncology’s Rubraca® (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups
From Clovis Oncology, Inc.
Via Business Wire
Tickers CLVS
Clovis Oncology Announces Second Quarter 2022 Operating Results and Provides Update on Clinical Development Programs
From Clovis Oncology, Inc.
Via Business Wire
Tickers CLVS
CORRECTING and REPLACING Clovis Oncology to Announce Second Quarter 2022 Financial Results and Host Webcast Conference Call on August 8
From Clovis Oncology, Inc.
Via Business Wire
Tickers CLVS
Clovis Oncology’s Rubraca® (Rucaparib) as First-Line Maintenance Treatment Significantly Improves Progression-Free Survival in Women with Advanced Ovarian Cancer in Primary Efficacy Analyses Regardless of BRCA Mutation and HRD Status
From Clovis Oncology, Inc.
Via Business Wire
Tickers CLVS
Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 at SNMMI Annual Meeting
From Clovis Oncology, Inc.
Via Business Wire
Tickers CLVS
Clovis Oncology to Present at the BofA Securities 2022 Healthcare Conference
From Clovis Oncology, Inc.
Via Business Wire
Tickers CLVS
Clovis Oncology Announces First Quarter 2022 Operating Results and Provides Update on Clinical Development Programs
From Clovis Oncology, Inc.
Via Business Wire
Tickers CLVS
Clovis Oncology Highlights Rubraca® (Rucaparib) and FAP-2286 Data to be Presented at 2022 ASCO Annual Meeting
From Clovis Oncology, Inc.
Via Business Wire
Tickers CLVS
Clovis Oncology to Announce First Quarter 2022 Financial Results and Host Webcast Conference Call on May 4
From Clovis Oncology, Inc.
Via Business Wire
Tickers CLVS
Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022
From Clovis Oncology, Inc.
Via Business Wire
Tickers CLVS
Clovis Oncology’s Rubraca® (Rucaparib) Significantly Improves Progression-Free Survival in First-line Maintenance Treatment in Women with Ovarian Cancer Regardless of Their Biomarker Status in Phase 3 ATHENA-MONO Trial
From Clovis Oncology, Inc.
Via Business Wire
Tickers CLVS
Clovis Oncology and Evergreen Theragnostics Initiate Development and Manufacturing Services Agreement for Actinium-225-Labeled FAP-2286
From Clovis Oncology, Inc.
Via Business Wire
Tickers CLVS
Clovis Oncology Highlights Ongoing Phase 1/2 LuMIERE Clinical Study and Multi-Tumor Imaging Investigator-Initiated Trial of FAP-2286 Fibroblast Activation Protein-Targeted Radiotherapy Candidate at an Upcoming Nuclear Medicine Meeting
From Clovis Oncology, Inc.
Via Business Wire
Tickers CLVS
Clovis Oncology Announces 2021 Operating Results and Anticipated 2022 Development Milestones
From Clovis Oncology, Inc.
Via Business Wire
Tickers CLVS
Clovis Oncology to Announce Fourth Quarter 2021 and Year End 2021 Financial Results and Host Webcast Conference Call
From Clovis Oncology, Inc.
Via Business Wire
Tickers CLVS
Clovis Oncology Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2021
From Clovis Oncology, Inc.
Via Business Wire
Tickers CLVS
Clovis Oncology Highlights FAP-2286 Preclinical Data Presented at the Targeted Radiopharmaceuticals Summit
From Clovis Oncology, Inc.
Via Business Wire
Tickers CLVS
Clovis Oncology Announces Third Quarter 2021 Operating Results
From Clovis Oncology, Inc.
Via Business Wire
Tickers CLVS
Clovis Oncology to Announce Third Quarter 2021 Financial Results and Host Webcast Conference Call on November 3
From Clovis Oncology, Inc.
Via Business Wire
Tickers CLVS
Clovis Oncology and ITM Announce Lutetium-177 Clinical Supply Agreement
From Clovis Oncology, Inc.
Via Business Wire
Tickers CLVS
Pan-Cancer Analysis Suggests Fibroblast Activation Protein (FAP) is an Attractive Target for Peptide-Targeted Radionuclide Therapy with FAP-2286
From Clovis Oncology, Inc.
Via Business Wire
Tickers CLVS
Clovis Oncology Retires Remaining 2021 Notes and Raises Additional Capital through its ATM Equity Offering Program
From Clovis Oncology, Inc.
Via Business Wire
Tickers CLVS
Clovis Oncology Announces Renewal of At-The-Market Equity Offering Program
From Clovis Oncology, Inc.
Via Business Wire
Tickers CLVS
Clovis Oncology Announces Second Quarter 2021 Operating Results
From Clovis Oncology, Inc.
Via Business Wire
Tickers CLVS
Clovis Oncology to Announce Second Quarter 2021 Financial Results and Host Webcast Conference Call on August 4
From Clovis Oncology, Inc.
Via Business Wire
Tickers CLVS
Clovis Oncology Appoints Dr. Ronit Simantov to its Board of Directors
From Clovis Oncology, Inc.
Via Business Wire
Tickers CLVS
Initial Clinical Experience of FAP-2286 in Independent Named Patient Use Published in The Journal of Nuclear Medicine
From Clovis Oncology, Inc.
Via Business Wire
Tickers CLVS
Clovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open for Enrollment
From Clovis Oncology, Inc.
Via Business Wire
Tickers CLVS
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
TOP
Email a Story